Breaking News Instant updates and real-time market news.

EOLS

Evolus

$14.95

-1.04 (-6.50%)

04:55
08/15/19
08/15
04:55
08/15/19
04:55

Evolus management to meet with SunTrust

Meeting to be held in Boston, MA on August 15 hosted by SunTrust.

  • 15

    Aug

  • 04

    Sep

EOLS Evolus
$14.95

-1.04 (-6.50%)

07/11/19
WELS
07/11/19
NO CHANGE
Target $16
WELS
Market Perform
Evolus investors should keep eye on progressing Korean case, says Wells Fargo
A press report from Korea Biomedical Review indicates that the Seoul Central District Court has begun to test whether Nabota, the botulinum toxin of Daewoong Pharmaceutical, forms spores in the natural environment as an attempt to help decide the litigation between South Korean toxin manufacturers, Medytox and Daewoong, Wells Fargo analyst David Maris tells investors in a research note. Medytox sued Daewoong in 2017 alleging that Daewoong stole its botulinum toxin strain to manufacture its own, and thereby licensed U.S. cosmetic rights out to Evolus (EOLS) with a stolen botulinum toxin strain, Maris adds, while noting the report also said the first ruling should come in Q4 of this year. After speaking with company, Maris says the development is not unexpected. He believes, however, that investors should be aware of the progress and status of the litigation. The analyst keeps a Market Perform rating on Evolus shares with a $16 price target.
07/11/19
WELS
07/11/19
NO CHANGE
WELS
Market right in seeing rebate news as risk to pharmaceuticals, says Wells Fargo
Most pharmaceuticals stocks are down today due to a number of factors, including reports that the Trump Administration is abandoning its plan to lower drug prices by eliminating or restricting pharmacy benefit manager rebating, Wells Fargo analyst David Maris tells investors in a research note. The analyst believes the market is correctly interpreting the move as a potential risk to drugmakers. The absence of a rebating fix "does not mean there will not be a plan to address drug prices, but perhaps a greater risk that the absence of a rebate fix will put additional pressure to come up with ways to actually lower prices in ways that could more greatly impact drug makers than the rebating fix would have," contends Maris. He points out that companies with large cash-pay components of their business, like Allergan (AGN), Establishment Labs (ESTA), Evolus (EOLS), GlaxoSmithKline (GSK), Perrigo (PRGO), Revance (RVNC) and Sientra (SIEN), do not seem to be under as much pressure today as some of their more generic or pharma-concentrated peers. Maris says his Outperform ratings on Allergan, Establishment and Sientra are in part due to their cash-pay concentration
07/31/19
STFL
07/31/19
NO CHANGE
STFL
Buy
Physician survey bodes well for Evolus and Revance, says Stifel
Stifel analyst Annabel Samimy said her survey of 50+ physicians in late June lead her to now believe that new toxins could have penetrations that exceed her current market-share estimates. The survey bodes well for Evolus (EOLS) in the near-term and for both Evolus and Revance (RVNC) in the longer-term while also indicating that Allergan's (AGN) Botox franchise may be more vulnerable than previously thought, Samimy tells investors. She previously had Evolus' Jeuveau reaching a peak market share of 15% and Revance's DaxibotulinumtoxinA reaching 20% shares by 2027, but her new "base case" assumes that Jeuveau peaks at 20% share and Daxi peaks at 25%, noted Samimy, who took down her Botox market share forecast for 2027 to 50%. Samimy raised her price target on Evolus shares to $33 from $30 and keeps a $50 price target on Revance while maintaining Buy ratings on both stocks.
08/13/19
JMPS
08/13/19
NO CHANGE
Target $30
JMPS
Outperform
Evolus price target lowered to $30 from $35 at JMP Securities
JMP Securities analyst Donald Ellis lowered his price target on Evolus to $30 after its Q2 earnings miss and to reflect the updated share count for the stock in his valuation model. The analyst is keeping his Outperform rating however, noting that the company's launch of JEUVEAU on May 15 has exceeded expectations on several metrics, including "physician practices joining the JET trial" and patient satisfaction. Ellis maintains his expectation for JEUVEAU to achieve the management's target of a #2 position in the U.S. aesthetic toxin market.

TODAY'S FREE FLY STORIES

PROS

ProSight

$18.71

-0.5 (-2.60%)

07:01
08/19/19
08/19
07:01
08/19/19
07:01
Initiation
ProSight initiated  »

ProSight initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULC

Fulcrum Therapeutics

$9.11

-0.14 (-1.51%)

07:01
08/19/19
08/19
07:01
08/19/19
07:01
Hot Stocks
Fulcrum Therapeutics intitiates Phase 2b clinical trial of losmapimod for FSHD »

Fulcrum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$48.46

1.55 (3.30%)

06:59
08/19/19
08/19
06:59
08/19/19
06:59
Recommendations
Dell Technologies analyst commentary  »

Dell Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

APTS

Preferred Apartment

$14.32

0.165 (1.17%)

06:59
08/19/19
08/19
06:59
08/19/19
06:59
Hot Stocks
Preferred Apartment makes joint venture investment in Virginia shopping center »

Preferred Apartment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PROS

ProSight

$18.71

-0.5 (-2.60%)

06:58
08/19/19
08/19
06:58
08/19/19
06:58
Initiation
ProSight initiated  »

ProSight initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$5.05

0.665 (15.18%)

06:58
08/19/19
08/19
06:58
08/19/19
06:58
Hot Stocks
Tailored Brands reaffirms Q2 SSS outlook »

The company expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 23

    Sep

ACM

Aecom

$32.97

0.53 (1.63%)

06:56
08/19/19
08/19
06:56
08/19/19
06:56
Hot Stocks
Aecom announces extension of tank operations contract »

AECOM announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EL

Estee Lauder

$179.26

3.89 (2.22%)

06:55
08/19/19
08/19
06:55
08/19/19
06:55
Hot Stocks
Estee Lauder sees 'strong consumer demand for high-quality products' in FY20 »

"The company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

TLRD

Tailored Brands

$5.05

0.665 (15.18%)

06:52
08/19/19
08/19
06:52
08/19/19
06:52
Earnings
Tailored Brands raises Q2 adjusted EPS view to 78c-80c from 65c-70c »

Q2 consensus 70c. Sees Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 23

    Sep

DRYS

DryShips

$3.83

0.065 (1.73%)

06:50
08/19/19
08/19
06:50
08/19/19
06:50
Hot Stocks
DryShips to be acquired by SPII Holdings for $5.25 per share in cash »

DryShips announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$5.05

0.665 (15.18%)

06:50
08/19/19
08/19
06:50
08/19/19
06:50
Earnings
Tailored Brands announces sale of corporate apparel business for $62M in cash »

Tailored Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 23

    Sep

DRYS

DryShips

$3.83

0.065 (1.73%)

06:49
08/19/19
08/19
06:49
08/19/19
06:49
Hot Stocks
Breaking Hot Stocks news story on DryShips »

DryShips to be acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDAY

Ceridian

$50.69

0.2 (0.40%)

06:49
08/19/19
08/19
06:49
08/19/19
06:49
Upgrade
Ceridian rating change  »

Ceridian upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

DECK

Deckers Brands

$134.33

1.39 (1.05%)

06:49
08/19/19
08/19
06:49
08/19/19
06:49
Upgrade
Deckers Brands rating change  »

Deckers Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

  • 25

    Sep

EL

Estee Lauder

$179.26

3.89 (2.22%)

06:48
08/19/19
08/19
06:48
08/19/19
06:48
Earnings
Estee Lauder sees FY20 adjusted EPS $5.90-$5.98, consensus $5.81 »

Reported net sales are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

EL

Estee Lauder

$179.26

3.89 (2.22%)

06:47
08/19/19
08/19
06:47
08/19/19
06:47
Earnings
Estee Lauder sees Q1 adjusted EPS $1.56-$1.59, consensus $1.55 »

Reported net sales are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

EL

Estee Lauder

$179.26

3.89 (2.22%)

06:45
08/19/19
08/19
06:45
08/19/19
06:45
Earnings
Estee Lauder reports Q4 EPS 64c, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BAC

Bank of America

$27.04

0.79 (3.01%)

, C

Citi

$63.46

2.13 (3.47%)

06:45
08/19/19
08/19
06:45
08/19/19
06:45
Periodicals
Updated Volcker Rule expected this week, WSJ reports »

An updated Volcker Rule…

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

USB

U.S. Bancorp

$52.25

0.99 (1.93%)

WFC

Wells Fargo

$44.40

1.01 (2.33%)

GS

Goldman Sachs

$199.39

3.2 (1.63%)

MS

Morgan Stanley

$39.94

0.85 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 06

    Sep

  • 11

    Sep

  • 12

    Sep

  • 12

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 16

    Oct

  • 27

    Oct

PCG

PG&E

$14.30

-0.08 (-0.56%)

06:44
08/19/19
08/19
06:44
08/19/19
06:44
Periodicals
PG&E holds on to sole rights to devise chapter 11 exit plan, WSJ reports »

A U.S. Bankruptcy Court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVGO

Livongo Health

$37.00

3.22 (9.53%)

06:42
08/19/19
08/19
06:42
08/19/19
06:42
Initiation
Livongo Health initiated  »

Livongo Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

ACM

Aecom

$32.97

0.53 (1.63%)

06:38
08/19/19
08/19
06:38
08/19/19
06:38
Upgrade
Aecom rating change  »

Aecom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCAT

Health Catalyst

$42.50

0.96 (2.31%)

06:37
08/19/19
08/19
06:37
08/19/19
06:37
Initiation
Health Catalyst initiated  »

Health Catalyst initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

NYNY

Empire Resorts

$8.35

-0.145 (-1.71%)

06:37
08/19/19
08/19
06:37
08/19/19
06:37
Hot Stocks
Empire Resorts to be acquired by Kien Huat, Genting Malaysia for $9.74 per share »

Empire Resorts announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DECK

Deckers Brands

$134.33

1.39 (1.05%)

06:36
08/19/19
08/19
06:36
08/19/19
06:36
Upgrade
Deckers Brands rating change  »

Deckers Brands upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

  • 25

    Sep

HCAT

Health Catalyst

$42.50

0.96 (2.31%)

06:35
08/19/19
08/19
06:35
08/19/19
06:35
Initiation
Health Catalyst initiated  »

Health Catalyst initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.